CD247 and ovarian carcinoma: For instance, one study developed anti‐CD133‐CD28‐41BB‐CD3ζ‐CAR‐NK92 cells targeting CD133‐positive ovarian cancer cells, while another designed anti‐CD24‐CD28‐41BB‐CD3ζ‐CAR‐NK92 cells to selectively eliminate CD24‐positive ovarian cancer cells.